Europe STD Diagnostics Market Report by Test Type, Technology, Location of Testing, End User, Countries and Company Analysis, 2026-2034

The Europe STD diagnostics market is expected to have a steady growth from USD 8.91 billion in 2025 to USD 15.10 billion in 2034, with a compound annual growth rate (CAGR) of 6.04% during the period from 2026 to 2034. The steady increase in the prevalence of STDs, the rising initiatives for the diagnosis of STDs, and the advances in technology for the diagnosis of STDs influence the growth in the market for STD diagnostics in the European region. The healthcare infrastructure in the region further fuels the demand for STD diagnostics in Europe.

Europe STD Diagnostics Market Forecast

(STD Diagnostics) - This generally pertains to the range of laboratory and point-of-care tests used for the detection of sexually transmitted diseases such as chlamydia, gonorrhea, syphilis, and HIV. The tests may include serologic tests, molecular tests such as polymerase chain reaction, rapid tests for antigens and antibodies, and other innovative self-testing alternatives. The main aim and objectives of performing STD diagnostics are to identify the infection accurately to be treated.
In Europe, the number of STD cases and the importance of healthcare monitoring have led to the popularity of STD diagnosis. In this region, healthcare organizations focus on encouraging pregnant women and high-risk groups to test for STDs in a bid to control their spread.

The prevalence of a sophisticated healthcare environment is a contributing factor to the acceptance level of superior diagnostic technologies such as molecular and multiplex testing platforms. Moreover, rising awareness and a lack of stigma associated with STD diagnostics due to education efforts and accessible fast and confidential testing have positively impacted their acceptance and utilization within Europe.

Market Changer in European STD Diagnostics Industry

Rising Burden of Sexually Transmitted Diseases

The rise in sexually transmitted disease infections in the European region is one of the major factors propelling the growth of the STD diagnostics market. The increase in reported chlamydia, gonorrhea, syphilis, and HIV cases has pressed the need for early and periodic screenings. The rise in urbanization, sexual behavior, and awareness about the disease among citizens has further encouraged the increase in the number of tests being conducted. Government and healthcare bodies are working to increase screenings among high-risk groups like young people, gay and bisexual men, and pregnant women. The sexually transmitted infection is on the rise in the European countries, with data released by the European Centre for Disease Prevention and Control showing that almost 100,000 new gonorrhea cases were reported, which is a record high and higher than 74,000 in 2022. It is also four times higher than reported cases 10 years ago.

Technological Advancements in Diagnostic Solutions

The increasing innovations being witnessed in the diagnostic technologies field have contributed significantly to the growth of the European market for STD diagnostics. Improvements seen in the field of molecular diagnostics technology, such as automation and digital innovations, have led to increased accuracy rates in test results. In addition to this, faster turnaround times and increased efficiency in laboratories have also led to the increased adoption of this technology. Another technology being seen to gain greater acceptance is the concept of "multiplexing" technology. With this technology, multiple pathogens can be tested from a single sample at the same time. With advancements seen in technologies such as increased sensitivity and specificity rates, health experts’ trust in test results has also increased. In December 2025, Roche announced the receipt of the CE Mark approval for its cobas BV/CV assay. The cobas BV/CV assay is known to provide accurate results of specific bacteria or yeasts causing both BV and CV infections from vaginal samples obtained from symptomatic patients collected through the cobas PCR Media proprietary tube.

Increased Availability of Screening & Preventive Healthcare Programs

Screening programs launched through government support and preventive healthcare programs are significantly contributing to the growth of the market for diagnosing STDs in the European market. Some important programs initiated in the context of preventive care are encouraging repeat testing. SHIELD Joint Action is funded to the tune of nearly EUR 20 million through the EU4Health program. SHIELD is an EU joint action involving 25 Member States, running until October 2028. It seeks to prevent infections that lead to cancer, such as HPV, hepatitis B/C, HIV, and tuberculosis, through making it easier to vaccinate, test, and treat.

Challenge in the Europe STD Diagnostics Market

Fragmentation of the Healthcare Systems

One of the most important factors that pose a challenge to the Europe STD diagnostics market is the fragmented nature of health care systems practiced in Europe. What might be approved in France would not be easily approved in the UK due to many factors like government funding, cost, quality, and demography. Diagnostics companies might have to hold back their entry into some markets if it takes time to get the lucrative markets first.

Small Diagnostics Companies’ Problem

Small diagnostic companies have a tough time dealing with the health care systems adopted in Europe. An important factor that small diagnostic companies might have to deal with is finding it tough to cope with the health care systems of many European countries. Stigma and Lack of Patient Engagement Despite the heightened sensitization, the social stigmas associated with sexually transmitted diseases have hampered the testing process. Social acceptance and the absence of proper education have deterred people from undergoing testing. This phenomenon is seen, especially in conservative areas, where the testing rate is lower than the ideal set by the social healthcare services. The reduced patient engagement affects the success of the testing programs, thereby hindering the growth of the market. Although the use of self-testing and point-of-care technologies helps overcome the problem, social challenges still exist.

Europe Syphilis Testing Market

The market for syphilis testing in the European market is witnessing renewed interest owing to the rising incidence of syphilis infections and the potential for serious complications if the condition is not treated. Screening is encouraged as a focus area of antenatal care services, as well as blood screening programs, as well as surveillance of high-risk populations. Laboratory-based serological testing is the mainstay of syphilis testing, complemented by algorithms to ensure accuracy through confirmatory testing. There is renewed interest due to the importance of congenital syphilis prevention programs to ensure regular antenatal screening programs remain enhanced as a result of increased awareness. Rapid tests have also gained popularity as a supplement to outreach programs to ensure immediate referral to care programs.

Europe HIV Testing Market

The European HIV testing market is distinguished by early diagnosis, accessibility, and prevention. Expanded testing, including screening in regular practice and among high-risk populations, has led to an increase in test numbers. Laboratory immunoassays are still in practice, but there is a trend towards rapid testing, as well as self-testing, due to their convenience. The need to reduce the number of untreated infections, as well as the need to refer patients promptly to treatment, is fueling interest in new testing platforms. Technologic advances, further reducing diagnostic times, will make testing even more effective. The market is stable, fully mature, but still growing along the lines of prevention and decentralized testing.

Europe STD Molecular Diagnostics Market

The molecular diagnostics market is one of the most rapidly growing segments of the Europe market for STD testing. Molecular technology enables higher levels of sensitivity and specificity, and thus it is the technology of choice for diagnostic testing of diseases like chlamydia and gonorrhea. Its use is prevalent among centralized laboratories and hospital settings, where the test volumes are substantial. The multiplex molecular technology lowers the costs of testing and is efficient, and thus it is ideal for use among the large healthcare providers. With the advent of automation of the laboratories and connectivity, molecular testing will soon become ubiquitous within the EU. This segment is priced higher and accounts for the majority of the market, although the initial capital outlays are substantial.

Europe Std Rapid Point-of-Care Platform Market

Rapid point-of-care STD diagnostic platforms are gaining popularity because of their capacity to provide fast results, allowing same-visit treatments. Such diagnostic platforms are particularly useful in STD clinics, emergency care, and mobile programs where closely followed-up patients may be difficult to find. Improvements in the accuracy of these platforms have helped boost their acceptance in medical circles. Though some cost issues are being experienced, the medical advantages, particularly in the reduction of STD spread and enhanced compliance, are contributing to the ongoing acceptance. There is an evolving trend towards more advanced rapid techniques that provide both fast results and accuracy, making them more useful in the medical field in Europe.

Europe STD Diagnostics Hospitals & Clinics Market

Hospital and clinic user communities account for the largest market by end-user segment for the Europe STD diagnostics market. The hospitals deal with complex diagnostic issues, while the clinics handle the regular diagnoses of patients apart from the complex ones in hospitals. The hospitals demand high-capability analyzers for diagnosis, while the clinics demand rapid analyzers for faster patient turnover time for diagnosis of STD. The ability of the analyzers to interface with the EMR systems of these institutions trends to be an important purchasing consideration among these users.

France STD Diagnostics Market

The STD diagnostics market in France enjoys a well-structured healthcare system with a high level of government support for healthcare in France. The national screening programs, especially for HIV and syphilis, create a steady demand for diagnostics in France. The advanced tests are largely done at the centralized labs, while the community health centers assist in overall screening programs in France. The preventative policies for health in France encourage overall screenings over symptomatic tests for various conditions, like STDs. The overall market for diagnostics in France is mature with a steady advancement towards molecular diagnostics technology in France. Free Self-Collection Program The program was launched in July 2025 under the country’s health insurance system (Assurance Maladie), marking the first-ever free, home-order self-testing kit program for women aged between 18-25 for Chlamydia/Gonorrhoea in the entire continent of Europe.

Germany Chlamydia Trachom

In Europe, the most technically proficient markets for the diagnosis of STDs are in Germany. The country boasts a strong lab infrastructure and a high healthcare spending environment conducive to the adoption of molecular diagnostics and automated platforms. Private and hospital labs in particular act as the major growth driver in the German market, inclined towards high-performance and high-throughput systems. SANGE (sangerange.org) emphasizes the importance of screening and the “value of prevention in healthcare.” “STD testing can be a stressful and uncomfortable experience. Undignified and humiliating conditions and the trauma associated with conventional STD tests can often deter many people from being tested for the fear of embarrassment and the pain associated with the STD tests.” Dec 2025, Jerusalem-based Salignostics, a company that boasts a world’s first saliva-based pregnancy test, began its first commercial sales in the German pharmacy chain Rossmann, which is the second-largest drugstore chain in the world and the largest in the German-speaking countries. Distribution in the chain is handled by Mertz Pharma Handel GmbH, Salignostics’s commercial partner.

UK STD Diagnosis Market

The UK STD diagnostics market is well connected with the healthcare goals and care pathways. The screening and sexual health centers create a high demand for both laboratory and rapid tests. The healthcare system is focused on early diagnosis and prevention, and thus holds the testing volumes high. The adoption rate is high, and innovation is being adopted in molecular and point-of-CARE tests, which help streamline the healthcare service delivery. The budget holds limitations in procurement, but the clinical and public health outcomes play important roles. The UK market is still focusing on cost control and innovation, thus allowing steady growth. December 2024, Abingdon Health plc, a global company that is a world-leading developer, manufacturer, and distributor of high-quality, rapid diagnostic tests, is pleased to announce that it has signed a contract with US company Find Out From Home LLC regarding the evaluation, regulatory, and clinical testing of four sexually transmitted disease ("STD") tests.

Russia STD Diagnostics Market

The Russian market for diagnosing sexually transmitted diseases reflects variability and diverse development levels. Large cities possess well-developed laboratories, whereas less developed areas use simplified diagnostic techniques. Public health campaigns to manage the spread of sexually transmitted diseases are raising awareness and thus driving the demand for testing. Due to the sensitivity to costs and complexity, the markets are favorable to affordable and flexible diagnostic systems. The raised need for better surveillance and early diagnosis of sexually transmitted diseases holds latent growth opportunities.

Market Segmentation

Test Type

• Chlamydia Testing
• Gonorrhea Testing
• Syphilis Testing
• HPV Testing
• HSV Testing
• HIV Testing
• Trichomonas Testing
• Mycoplasma genitalium Testing
• Chancroid Testing

Technology

• Immunoassay‐based Methods
• Molecular Diagnostics
• Next-Generation Sequencing
• Biosensor / Microfluidics & Other Emerging Platforms

Location of Testing

• Central & Hospital Laboratories
• Rapid Point-of-Care Platforms
• Over-the-Counter / Home Self-Testing

End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Home Care / OTC

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Hologic Inc.
• Becton Dickinson and Company
• Danaher Corporation (Cepheid)
• Siemens Healthineers AG
• bioMérieux SA
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• Bio-Rad Laboratories Inc.